EUVIMEDEUVIMED entdecken
Crossref

Oncolytic Adenovirus Armoring with CXCL9 and IL15 Shows Potent Antitumor Activity and Boosts CAR-T Therapy for Prostate Cancer

Lin Fang, Xueyan Wang, Yi Zhang, Chen Zhang, Xiaoxiao Liu, Wanjing Li, Yuxin Zhang, Nan Sun, Junnian Zheng iD, Gang Wang

Human Gene Therapy · 01.06.2025 · 36 (11-12) · 884-901

DOI: 10.1089/hum.2024.254 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Gene Therapy, erschienen am 01.06.2025. Verfasst von Lin Fang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute, Xuzhou Medical University, Xuzhou, China. Hauptthemen laut MEDLINE: Adenoviridae, Chemokine CXCL9, Prostatic Neoplasms, Oncolytic Viruses. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenoviridaeChemokine CXCL9Prostatic NeoplasmsOncolytic VirusesImmunotherapy, AdoptiveOncolytic VirotherapyReceptors, Chimeric AntigenAnimalsMaleHumansMiceCell Line, TumorXenograft Model Antitumor AssaysGenetic VectorsTumor MicroenvironmentInterleukin-15

Stichwörter der Autor:innen

CXCL9IL15chimeric antigen receptor T celloncolytic adenovirusprostate cancer

Substanzen

Chemokine CXCL9Receptors, Chimeric AntigenCXCL9 protein, humanIL15 protein, humanInterleukin-15

Autor:innen und Institutionen

  • Cancer Institute, Xuzhou Medical University, Xuzhou, China.
  • Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
  • Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, China.
  • Department of Oncology, Xuzhou City Hospital of TCM, Xuzhou, Jiangsu, China.
  • Department of Oncology, The First People's Hospital of Yancheng, Yancheng, Jiangsu, China.

ORCID-Profile: Junnian Zheng

Zitieren

APA

Fang, L., Wang, X., Zhang, Y., Zhang, C., Liu, X., Li, W., Zhang, Y., Sun, N., Zheng, J., & Wang, G. (2025). Oncolytic Adenovirus Armoring with CXCL9 and IL15 Shows Potent Antitumor Activity and Boosts CAR-T Therapy for Prostate Cancer. Human Gene Therapy, 36(11-12), 884-901. https://doi.org/10.1089/hum.2024.254

Vancouver

Fang L, Wang X, Zhang Y, Zhang C, Liu X, Li W, et al. Oncolytic Adenovirus Armoring with CXCL9 and IL15 Shows Potent Antitumor Activity and Boosts CAR-T Therapy for Prostate Cancer. Human Gene Therapy. 2025;36(11-12):884-901. doi:10.1089/hum.2024.254

BibTeX
@article{Fang2025,
  author = {Fang, Lin and Wang, Xueyan and Zhang, Yi and Zhang, Chen and Liu, Xiaoxiao and Li, Wanjing and Zhang, Yuxin and Sun, Nan and Zheng, Junnian and Wang, Gang},
  title = {Oncolytic Adenovirus Armoring with CXCL9 and IL15 Shows Potent Antitumor Activity and Boosts CAR-T Therapy for Prostate Cancer},
  journal = {Human Gene Therapy},
  year = {2025},
  volume = {36},
  number = {11-12},
  pages = {884--901},
  doi = {10.1089/hum.2024.254}
}
Kostenlos starten →